DAMORA THERAPEUTICS, INC. Operating Lease, Liability, Noncurrent
DAMORA THERAPEUTICS, INC. (DMRA) had Operating Lease, Liability, Noncurrent of $53.00 thousand as of 2025-12-31, per its 10-K filed 2026-03-19.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:OperatingLeaseLiabilityNoncurrent · last filed 2026-03-19
- 2025-12-31: Operating Lease, Liability, Noncurrent $53.00K.
- 2025-09-30: Operating Lease, Liability, Noncurrent $57.00K.
- 2025-06-30: Operating Lease, Liability, Noncurrent $60.00K.
- 2025-03-31: Operating Lease, Liability, Noncurrent $60.00K.
| Period end | Operating Lease, Liability, Noncurrent |
|---|---|
| 2025-12-31 | $53.00K 10-K · filed 2026-03-19 |
| 2025-09-30 | $57.00K 10-Q · filed 2025-11-06 |
| 2025-06-30 | $60.00K 10-Q · filed 2025-08-05 |
| 2025-03-31 | $60.00K 10-Q · filed 2025-05-08 |
| 2024-12-31 | $61.00K 10-K · filed 2026-03-19 |
| 2023-12-31 | $66.00K 10-K · filed 2025-03-19 |
| 2023-09-30 | $112.00K 10-Q · filed 2023-11-06 |
| 2023-06-30 | $206.00K 10-Q · filed 2023-07-31 |
| 2023-03-31 | $234.00K 10-Q · filed 2023-04-28 |
| 2022-12-31 | $328.00K 10-K · filed 2024-03-08 |
| 2022-09-30 | $440.00K 10-Q · filed 2022-11-08 |
| 2022-06-30 | $305.00K 10-Q · filed 2022-07-29 |
| 2022-03-31 | $402.00K 10-Q · filed 2022-04-29 |
| 2021-12-31 | $448.00K 10-K · filed 2023-03-09 |
| 2021-09-30 | $511.00K 10-Q · filed 2021-11-04 |
| 2021-06-30 | $635.00K 10-Q · filed 2021-08-05 |
| 2021-03-31 | $544.00K 10-Q · filed 2021-05-04 |
| 2020-12-31 | $541.00K 10-K · filed 2022-02-17 |
| 2020-09-30 | $589.00K 10-Q · filed 2020-12-11 |
| 2019-12-31 | $211.00K 10-K · filed 2021-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |